Abstrakt
Gliomas are a primary malignancy of the central nervous system. Particularly high grade gliomas show poor prognosis with limited survival despite standard therapy.
A novel approach is needed to advance glioma management based on predictive diagnostics; targeted preventivemeasures, as well as patient stratification should be carried out as part of the individualization of treatment algorithms. Treatment personalization using targeted anticancer drugs and immunotherapy is the subject of extensive research in neuro-oncology.
Gene fusions were identified as an emerging therapeutic target for gliomas. In this article we describe our use of next-generation sequencing to identify targetable gene fusions.
We also discuss an innovative preventive, predictive, personalized medicine (PPPM) oriented approach to glioma management.